Beta Bionics heads into the back half of August with a striking contradiction at its core: short sellers are adding positions at their fastest rate in months, yet options traders are the most bullish they have been all year.
Short interest is the dominant story this week, and the numbers are genuinely aggressive. Bears have pushed exposure to 18.6% of the free float — up 10.4% in a single week and 16.3% over the past month. That puts the short position at roughly 8.2 million shares, the highest level in the 30-day data window. The official FINRA fortnightly figure confirms the trend, showing 7.6 million shares short with 6 days to cover. This is a crowded short by any reasonable measure for a stock in the medical device space.
The lending market tells a more nuanced story, though. Borrow availability has tightened sharply — dropping from above 180% two weeks ago to 129% now, a 24% move in one week — but it remains in territory that can be described as tight rather than stressed. Plenty of shares are still available relative to the size of the existing short. Cost to borrow is running at just 0.57%, barely above nominal, having eased slightly over the week even as SI climbed. The ORTEX short score has crept to 73.95, its highest reading in the tracked window, and factor ranks confirm the picture: the short score ranks in the bottom 4th percentile of the universe, while days-to-cover ranks in the 29th. Bears are building, but the mechanics of a squeeze are not yet in place — availability would need to tighten considerably further before borrow pressure intensifies.
Options traders are reading the setup very differently. The put/call ratio has dropped to 0.12, nearly two standard deviations below its 20-day average of 0.13, and is running at the most call-skewed level in recent weeks. That is an unusually bullish lean for a stock with this much short interest sitting against it — options participants appear to be positioning for upside rather than hedging downside exposure. The divergence between a crowded short and call-heavy options flow is the most interesting tension in the name right now.
The Street has leaned constructive through the summer. William Blair initiated coverage this week at Market Perform, adding a cautious voice to a panel that otherwise tilts bullish — UBS assumed the stock in late July with a Buy and a $22 target, Goldman Sachs maintains a Buy with a $19 target, and Truist raised its target to $22 from $18 in mid-July. The bull case rests on 54% year-over-year revenue growth, a 59.5% gross margin, and raised full-year guidance. Bears, represented most clearly by B of A's Neutral rating, point to rising cash burn from sales team expansion, an unproven patch pump product, and the company's pre-profitability status — the EV/EBITDA multiple is deeply negative at -8.3x, and the analyst recommendation divergence factor ranks in the 93rd percentile of the universe, flagging meaningful disagreement on the Street. The analyst consensus is Hold, with four analysts sitting at that rating.
On the institutional side, Divisadero Street Capital Management stands out — it reported a position of 3.1 million shares in mid-July, reflecting a new build of 2.6 million shares. That is a material addition by a single manager in a stock with roughly 45 million shares outstanding, and it sits as a counterweight to the short selling pressure building in the same period.
The most recent earnings print delivered a sharp reminder of the stock's event risk: BBNX fell 9.7% the day after its July 29 results and was down 12% over the five days that followed, despite the headline beat. The next event is due October 29. Between now and then, the key variable is whether the rising short position continues to absorb available borrow — if availability drops meaningfully below 100%, the cost-to-borrow dynamic could shift quickly and the call-heavy options positioning would become a far more charged setup.
See the live data behind this article on ORTEX.
Open BBNX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
